[Efficacy of cereton in acute ischemic stroke: results of the trial SOLNTSE].
We studied 95 patients with acute (no later than 24h after onset) carotid ischemic stroke. Patients of the main group (50 patients) received cereton in dose 4 ml (1000 mg) intravenously during 10 days in the combination with traditional treatment; 45 patients of the control group received only traditional treatment. Neurological deficit on NIHSS and vigilance on The Glasgow Coma Scale were assessed at baseline and in 5th, 7th and 19-21th days. The Barthel index was used to measure functional independence of the patient at the discharge from a hospital (21th day). The "cost-effectiveness" ratio, the cost of one score on the NIHSS and Barthel scales were calculated. The reduction in neurological deficit (p<0.05) and higher extent of functional independence were seen in the main group compared to the controls. Based on the "cost-effectiveness" analysis, the use of cereton was shown to be more effective for treatment of patients with acute ischemic stroke: the cost of the achievement of positive effect in patients of the control group receiving only traditional treatment was significantly higher (p<0.05).
P R
PR
Kamchatnov
B A
BA
Abusueva
M A
MA
Evzel'man
R G
RG
Esin
E V
EV
Kol'iak
L B
LB
Novikova
S V
SV
Prikazchikov
A G
AG
Riabov
Kh Ia
KhIa
Umarova
A N
AN
Boĭko
D000368:Aged; D002340:Carotid Artery Diseases / Q000150:complications*; D002343:Carotid Artery, Internal; D005260:Female; D015600:Glasgow Coma Scale; D005997:Glycerylphosphorylcholine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*
D005997:Glycerylphosphorylcholine